These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 37553165)
1. Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer. Tsibulak I; Fotopoulou C Int J Gynecol Cancer; 2023 Oct; 33(10):1627-1632. PubMed ID: 37553165 [TBL] [Abstract][Full Text] [Related]
2. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245 [TBL] [Abstract][Full Text] [Related]
3. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy. Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648 [TBL] [Abstract][Full Text] [Related]
4. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412 [TBL] [Abstract][Full Text] [Related]
5. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer. Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093 [TBL] [Abstract][Full Text] [Related]
8. Optimal primary therapy of ovarian cancer. Bookman MA Ann Oncol; 2016 Apr; 27 Suppl 1():i58-i62. PubMed ID: 27141074 [TBL] [Abstract][Full Text] [Related]
9. Surgery for advanced epithelial ovarian cancer. Hacker NF; Rao A Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():71-87. PubMed ID: 27884789 [TBL] [Abstract][Full Text] [Related]
10. Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery. Kumar A; Cliby WA Clin Obstet Gynecol; 2020 Mar; 63(1):74-79. PubMed ID: 31725415 [TBL] [Abstract][Full Text] [Related]
11. CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer. Classe JM; Ferron G; Ouldamer L; Gauthier T; Emambux S; Gladieff L; Dupre PF; Anota A Int J Gynecol Cancer; 2022 Aug; 32(8):1071-1075. PubMed ID: 35321888 [TBL] [Abstract][Full Text] [Related]
12. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4. Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411 [TBL] [Abstract][Full Text] [Related]